Design, Optimization, and Characterization of Lactoferrin-Loaded Chitosan/TPP and Chitosan/Sulfobutylether-β-cyclodextrin Nanoparticles as a Pharmacological Alternative for Keratoconus Treatment
Source abstract
Abstract
This research study describes the design, optimization, and characterization of two different types of chitosan-based nanoparticles as novel drug delivery systems of a protein drug, lactoferrin. A preclinical consistent base was obtained for both nanosystems, being considered as the first pharmacological treatment for keratoconus as an alternative to current invasive clinical methods. Both types of nanoparticles were obtained via the ionotropic gelation technique. The size and morphology of the nanoparticles were studied as a function of the preparation conditions. A mean size of 180.73 ± 40.67 nm, a size distribution [polydispersity index (PDI)] of 0.170 ± 0.067, and positive ζ-potential values, ranging from 17.13 to 19.89 mV, were achieved. Lactoferrin was successfully incorporated into both types of nanocarriers. In vitro release profiles showed a lactoferrin enhanced, prolonged, and controlled delivery from the polymeric matrix. These formulations also demonstrated no stability or cytotoxicity problems, as well as appropriate mucoadhesive properties, with a high permanence time in the ocular surface. Thus, both types of nanoparticles may be considered as nanocarriers for the controlled release of lactoferrin as novel topical ophthalmic drug delivery systems.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Ocular Surface and Contact Lens · Infant Nutrition and Health
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela (USC), Campus vida, Santiago de Compostela 15782, Spain
Clinical Neurosciences Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
Molecular Imaging Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
Clinical Pharmacology Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
Department of Surgery and Medical-Surgical Specialties. Ophthalmology Area, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela 15706, Spain
Paraquasil Group, University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela 15706, Spain
References (66)
Show source-provided references
1. 10.5497/wjp.v2.i2.4710.5497/wjp.v2.i2.47 ↗
2. 10.1016/j.jconrel.2012.05.04010.1016/j.jconrel.2012.05.040 ↗
3. 10.1088/0957-4484/19/18/18510110.1088/0957-4484/19/18/185101 ↗
4. 10.1016/j.ajo.2007.11.01710.1016/j.ajo.2007.11.017 ↗
5. 10.1016/j.ajo.2016.12.01510.1016/j.ajo.2016.12.015 ↗
6. 10.1016/j.clae.2010.04.00610.1016/j.clae.2010.04.006 ↗
7. 10.1097/ICO.000000000000072310.1097/ICO.0000000000000723 ↗
8. 10.1016/j.preteyeres.2018.05.00210.1016/j.preteyeres.2018.05.002 ↗
9. Lema I. · Mol. Vis. · 2010 · 16 · 2055
10. 10.1292/jvms.66.14910.1292/jvms.66.149 ↗
11. 10.1167/iovs.08-188210.1167/iovs.08-1882 ↗
12. 10.1016/j.biochi.2008.07.00710.1016/j.biochi.2008.07.007 ↗
13. 10.1038/s41598-017-13525-710.1038/s41598-017-13525-7 ↗
14. Gesto, M. I. L.; Sánchez, J. A. C.; Moreiras, T. S.; Perez, F. C. Biomarkers for Diagnosis and Prognosis of Corneal Ectatic Disorders. US Patent US15/551,3862018.
15. 10.1159/00032979410.1159/000329794 ↗
16. 10.1016/j.addr.2011.08.00310.1016/j.addr.2011.08.003 ↗
17. 10.1248/cpb.33.246910.1248/cpb.33.2469 ↗
18. 10.1016/j.carbpol.2016.04.11510.1016/j.carbpol.2016.04.115 ↗
19. 10.4103/2230-973X.8243210.4103/2230-973X.82432 ↗
20. 10.1016/j.carbpol.2011.01.04410.1016/j.carbpol.2011.01.044 ↗
21. Guideline, I.C.H. Stability Testing of New Drug Substances and Products, Q1A (R2); ICH Harmonised Tripartite, 2006; p 20.
22. 10.1208/ps01031110.1208/ps010311 ↗
23. 10.2174/15672010978704830210.2174/156720109787048302 ↗
24. 10.1016/j.snb.2010.01.06310.1016/j.snb.2010.01.063 ↗
25. 10.1016/S0278-6915(96)00100-710.1016/S0278-6915(96)00100-7 ↗
26. Loprieno, N. Alternative Methodologies for the Safety Evaluation of Chemicals in the Cosmetic Industry; CRC Press, 2019; p 233.10.1201/9780429283765 ↗
27. Salem, H.; Katz, S. A. Alternative Toxicological Methods; CRC Press, 2003; p 618.10.1201/9780203008799 ↗
28. Tchao R. · Alternative Methods in Toxicology · 1988 · 6 · 271
29. 10.1016/0887-2333(94)90159-710.1016/0887-2333(94)90159-7 ↗
30. 10.1177/026119290503301s0910.1177/026119290503301s09 ↗
31. Wallig M. A. · 2018 · 673
32. 10.1016/0278-6915(85)90030-410.1016/0278-6915(85)90030-4 ↗
33. 10.1016/0887-2333(90)90147-L10.1016/0887-2333(90)90147-L ↗
34. 10.1016/0887-2333(93)90055-A10.1016/0887-2333(93)90055-A ↗
35. 10.3390/biomimetics402003210.3390/biomimetics4020032 ↗
36. 10.1016/j.jcis.2011.12.06310.1016/j.jcis.2011.12.063 ↗
37. 10.2174/15672010978704828510.2174/156720109787048285 ↗
38. 10.1021/mp300382n10.1021/mp300382n ↗
39. 10.1039/c2an35863h10.1039/c2an35863h ↗
40. Fernández-Ferreiro A. · Invest. Ophthalmol. Vis. Sci. · 2017 · 58 · 772
41. 10.1016/j.nantod.2016.06.00710.1016/j.nantod.2016.06.007 ↗
42. 10.1162/15353500332255687710.1162/153535003322556877 ↗
43. 10.1016/j.cmpb.2010.01.00710.1016/j.cmpb.2010.01.007 ↗
44. 10.1517/17425247.3.4.46310.1517/17425247.3.4.463 ↗
45. 10.1016/j.ijpharm.2009.04.00910.1016/j.ijpharm.2009.04.009 ↗
46. 10.1023/B:PHAM.0000012145.49054.6c10.1023/B:PHAM.0000012145.49054.6c ↗
47. 10.1016/j.ijpharm.2005.03.02710.1016/j.ijpharm.2005.03.027 ↗
48. 10.1016/j.ijpharm.2011.04.03110.1016/j.ijpharm.2011.04.031 ↗
49. Sohrabi S. M. · Mol. Biol. Res. Commun. · 2014 · 3 · 85
50. 10.1016/j.colsurfb.2009.08.04910.1016/j.colsurfb.2009.08.049 ↗
51. 10.1016/j.ijpharm.2007.03.00510.1016/j.ijpharm.2007.03.005 ↗
52. 10.1155/2018/526097610.1155/2018/5260976 ↗
53. Partheniades E. · 2009 · 4710.1016/B978-1-85617-556-2.00003-2 ↗
54. 10.1038/s41598-018-23064-410.1038/s41598-018-23064-4 ↗
55. 10.1080/0363904080197429510.1080/03639040801974295 ↗
56. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
57. 10.1016/S0006-3495(01)75844-410.1016/S0006-3495(01)75844-4 ↗
58. 10.1517/17425247.2011.58633410.1517/17425247.2011.586334 ↗
59. 10.1023/B:PHAM.0000026432.75781.cb10.1023/B:PHAM.0000026432.75781.cb ↗
60. Sarmento B. · 201210.1002/9781119962977 ↗
61. 10.1016/j.addr.2005.07.00810.1016/j.addr.2005.07.008 ↗
62. 10.1002/jps.2178310.1002/jps.21783 ↗
63. 10.1016/j.jconrel.2013.07.02710.1016/j.jconrel.2013.07.027 ↗
64. 10.3390/pharmaceutics1203026910.3390/pharmaceutics12030269 ↗
65. 10.1016/j.ijpharm.2013.02.01510.1016/j.ijpharm.2013.02.015 ↗
66. 10.1016/j.carbpol.2011.01.04410.1016/j.carbpol.2011.01.044 ↗